Recent Updates
Recently added Catalysts

ABT-072

Phase 2

Hepatitis C Virus Infection | Small molecule | Infectious Disease |AbbVie Inc.|Last Updated: Apr 1, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment5

FDA Designations

No designations recorded

Clinical trial landscape

ABT-072 · 1 trial · 1 indication

Phase 2 1
NCT00872196A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 StudiesHepatitis C Virus Infection
COMPLETED5 Analytics
PHASE2COMPLETED
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
Hepatitis C Virus Infection
NCT008721965
Unlock trial analytics

Study Endpoints

Primary Endpoints

Analysis of the prevalence of resistance of specific mutations over time will be summarized.
Approximately 48 weeks.
Analysis of the degree of phenotypic resistance (fold change in susceptibility of ABT-072 compared to wild-type virus) will also be summarized.
Approximately 48 weeks.

Secondary Endpoints

Summary of serious adverse events related to study procedures only.
Approximately 48 weeks.
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP

Treatment Arms

ArmTypeDescription
1 - Follow-up StudyOTHERThis is a follow-up study with no treatment and only samples being collected.

Interventions

NameTypeDescription
ABT-072DRUGBlood samples are being taken from subjects previously treated with ABT-072.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: \- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072. Exclusion Criteria: \- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about ABT-072

What is ABT-072 used for?

ABT-072 is an investigational small molecule being developed for the treatment of Hepatitis C Virus (HCV) infection. It is a direct-acting antiviral agent studied in patients with chronic HCV infection. The drug is currently in clinical development and has not been approved by regulatory authorities.

Who makes ABT-072?

ABT-072 is being developed by AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company. The drug is an investigational small molecule for the treatment of Hepatitis C Virus infection and is currently in Phase 2 clinical development.

What phase is ABT-072 in?

ABT-072 is in Phase 2 clinical development for the treatment of Hepatitis C Virus infection. It is an investigational drug and has not received regulatory approval. The drug is being studied in a completed Phase 2 trial that assessed resistance to ABT-072 in HCV-infected subjects.

What clinical trials is ABT-072 in?

ABT-072 has been studied in one completed Phase 2 clinical trial, NCT00872196, which was a follow-up study to assess resistance to ABT-072 in HCV-infected subjects who had received the drug in prior studies. The trial enrolled 5 participants in the United States and was not randomized or double-blinded.

Is ABT-072 the same as any other drug?

ABT-072 is a distinct investigational compound developed by AbbVie Inc. for Hepatitis C Virus infection. No alternative names for this drug have been reported. It is a small molecule antiviral agent that is being evaluated in clinical trials for its safety and efficacy.